BR112022003584A2 - Compostos de pirrolopirimidina inibidores de perk - Google Patents

Compostos de pirrolopirimidina inibidores de perk

Info

Publication number
BR112022003584A2
BR112022003584A2 BR112022003584A BR112022003584A BR112022003584A2 BR 112022003584 A2 BR112022003584 A2 BR 112022003584A2 BR 112022003584 A BR112022003584 A BR 112022003584A BR 112022003584 A BR112022003584 A BR 112022003584A BR 112022003584 A2 BR112022003584 A2 BR 112022003584A2
Authority
BR
Brazil
Prior art keywords
pyrrolopyrimidine compounds
perk inhibitor
perk
compounds
inhibitor
Prior art date
Application number
BR112022003584A
Other languages
English (en)
Portuguese (pt)
Inventor
An-Hu Li
J Mulvihill Mark
David Surman Matthew
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of BR112022003584A2 publication Critical patent/BR112022003584A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022003584A 2019-08-29 2020-08-28 Compostos de pirrolopirimidina inibidores de perk BR112022003584A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (1)

Publication Number Publication Date
BR112022003584A2 true BR112022003584A2 (pt) 2022-05-24

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003584A BR112022003584A2 (pt) 2019-08-29 2020-08-28 Compostos de pirrolopirimidina inibidores de perk

Country Status (12)

Country Link
US (1) US20220356186A1 (https=)
EP (1) EP4021908A1 (https=)
JP (1) JP2022546414A (https=)
KR (1) KR20220066290A (https=)
CN (1) CN114710956A (https=)
AU (1) AU2020336975A1 (https=)
BR (1) BR112022003584A2 (https=)
CA (1) CA3152508A1 (https=)
IL (1) IL290889A (https=)
MX (1) MX2022002446A (https=)
PH (1) PH12022550491A1 (https=)
WO (1) WO2021041975A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585606A (zh) 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
WO2022216680A1 (en) * 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
JP6493218B2 (ja) * 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016085160A2 (ko) * 2014-11-28 2016-06-02 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
ES2965081T3 (es) * 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
RS65914B1 (sr) * 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja

Also Published As

Publication number Publication date
US20220356186A1 (en) 2022-11-10
IL290889A (en) 2022-04-01
CN114710956A (zh) 2022-07-05
KR20220066290A (ko) 2022-05-24
PH12022550491A1 (en) 2023-02-06
EP4021908A1 (en) 2022-07-06
MX2022002446A (es) 2022-06-02
JP2022546414A (ja) 2022-11-04
WO2021041975A1 (en) 2021-03-04
AU2020336975A1 (en) 2022-03-31
CA3152508A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
SA521422303B1 (ar) مثبطات عضو عائلة الكنيسين 18 أ
JOP20230170A1 (ar) مثبطات cdk2 وطرق لاستخدامها
MX2022002443A (es) Compuestos inhibidores de perk.
CR20230103A (es) Análogos de rapamicina ligados a c40, c28 y c32 como inhibidores de mtor
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201691135A1 (ru) Новые ингибиторы глутаминазы
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CL2021002681A1 (es) Inhibidores de la dihidroorotato deshidrogenasa.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
MX2024002391A (es) Inhibidores de indolina de kif18a.
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
WO2024026483A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same
JOP20230091A1 (ar) مثبط magl
EA202190452A1 (ru) Ингибиторы cdk8/19
ZA202106519B (en) Caspase inhibitors and methods of use thereof
EA202192237A1 (ru) Кристаллические формы ингибитора jak2
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.